Moderna's INT Outlook Strengthens After Phase 3 Melanoma Data, Morgan Stanley Says

MT Newswires Live00:22

Moderna's (MRNA) phase 3 adjuvant melanoma data establishes clinical proof of concept for individualized neoantigen therapies, or INT, while interim data from a phase 2 kidney cancer trial would provide the next input into the potential breadth of opportunity for the drug, Morgan Stanley said in a note Tuesday.

The investment firm raised its peak sales estimate for individualized neoantigen therapies to $32 billion from $24 billion, profit-share assumption, and terminal growth rate in the firm's discounted cash flow model following the presentation of the phase 3 melanoma data

Morgan Stanley said a key opinion leader called the phase 3 melanoma results groundbreaking, citing a 0.58 hazard ratio for recurrence-free survival, and projected a 60% to 70% probability of success for INT in renal cell carcinoma versus about 50% in lung cancer.

The next key catalyst is an interim analysis of Moderna's phase 2 renal cell carcinoma trial, expected later this year or early 2027, the firm said.

Morgan Stanley maintained its equal weight rating on the stock and raised its price target to $200 from $95.

Moderna shares were down 3.9% in Tuesday trading.

Price: 206.91, Change: -8.37, Percent Change: -3.89

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment